Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma

NCT03434769 is registered in ClinicalTrials.gov with Benjamin Tomlinson as lead sponsor.

NCT NCT03434769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03434769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma
Lead sponsor
Benjamin Tomlinson
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 9, 2018
Completion date
February 29, 2036
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma